In this episode (16:05), Medicom’s correspondent covers 6 presentations from the Skin Inflammation & Psoriasis International Network (SPIN) annual meeting, held in Paris, France from 06-08 July 2022.
The topics discussed are:
- Bimekizumab versus secukinumab in psoriasis: superior response and maintenance rates with IL-17A/17F inhibition
In the phase 3b BE RADIANT trial, the IL-17A/17F antibody bimekizumab outperformed secukinumab in primary response rates and maintenance. Patients who achieved Psoriasis Area and Severity Index (PASI) ≤2 at week 16 showed effect continuation to 48 weeks in 88.0% and 79.1% of those treated with bimekizumab and secukinumab, respectively. - Ixekizumab: high clearance rates of difficult-to-treat areas in children with psoriasis
Body areas that may be of special relevance to the quality-of-life in paediatric patients showed a good response to ixekizumab after 108 weeks of treatment. Genital psoriasis, for example, was cleared in 87.5% of patients. - Certolizumab shows benefit for anxiety and depression in psoriasis
A pooled analysis of the phase 3 CIMPASI-1 and -2 trials revealed that certolizumab, used to treat psoriasis, may also simultaneously ameliorate depression or anxiety. Almost half of the depressive and nearly one-third of the anxiety patients achieved a status of “no anxiety/depression present”. - Generalised pustular psoriasis: IL-36 inhibitor effective across all subgroups
A subgroup analysis of the phase 2 trial Effisayil 1 demonstrated the efficacy of the interleukin (IL)-36 receptor antibody spesolimab across different pre-specified subgroups. Interestingly, spesolimab was also effective in patients with IL36RN mutation status. - GPP flares: one-quarter of patients receive no treatment
An American study assessed the characteristics and management of general pustular psoriasis (GPP) flares as depicted in US healthcare records from 2015 to 2020. Despite the severe symptoms, the study revealed a distinct under-treatment: many patients were not treated at all or were prescribed topical steroids only. - Better social and sexual life associated with greater PASI reductions in patients with psoriasis
An analysis of the phase 3 trials VOYAGE 1 and VOYAGE 2 revealed that therapy with guselkumab and adalimumab improved social relationships and sexual health in patients with psoriasis compared with placebo at week 12. At week 24, a significant difference in favour of guselkumab versus adalimumab was also found. In general, impairment in these domains was more pronounced in women.
Enjoy listening!
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares »
« Letter from the Editor Next Article
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares »
Table of Contents: SPIN 2022
Featured articles
Letter from the Editor
IMIDs in Adults and Children: New Developments
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
Men on biologics report fewer adverse events than women
Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs
Psoriasis: The Beat Goes On
Systemic treatment for psoriasis: what is on the horizon?
Topical therapy in psoriasis: an important partner in combination therapy
GPP flares: pronounced undertreatment is common
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas
Psoriasis patients see great benefit in achieving complete skin clearance
The Future Is Bright for Vitiligo
Predilection sites for skin signs of vitiligo disease activity determined
Where Are We Now in Hidradenitis Suppurativa
IHS4 better suited as an outcome measure in HS trials?
New treatments for HS: IL-17 inhibitors next in practice?
New Treatment Options in Alopecia Areata
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Best of the Posters
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Dose tapering in psoriasis is associated with a low relapse rate
Related Articles
December 17, 2020
Selective IL-23 blocker shows potential in psoriasis treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com